{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T06:28:22Z","timestamp":1725258502119},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,10,6]],"date-time":"2015-10-06T00:00:00Z","timestamp":1444089600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2015,10,6]],"date-time":"2015-10-06T00:00:00Z","timestamp":1444089600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm underlain by the formation of BCR-ABL1 \u2013 an aberrant tyrosine kinase \u2013 in the leukaemic blasts. Long-term survival rates in CML prior to the advent of tyrosine kinase inhibitors (TKIs) were dismal, albeit the incidence of secondary malignancies was higher than that of age-matched population. Current figures confirm the safety of TKIs with conflicting data concerning the increased risk of secondary tumours. We postulate that care has to be taken when distinguishing between coexisting, secondary-to-treatment and second in sequence, but independent tumourigenic events, in order to achieve an unbiased picture of the adverse effects of novel treatments. To illustrate this point, we present a case of a patient in which CML and peripheral T-cell lymphoma (PTCL) coexisted, although the clinical presentation of the latter followed the achievement of major molecular response of CML to TKIs.<\/jats:p>","DOI":"10.1038\/srep14829","type":"journal-article","created":{"date-parts":[[2015,10,6]],"date-time":"2015-10-06T09:58:11Z","timestamp":1444125491000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Molecular investigation of coexistent chronic myeloid leukaemia and peripheral T-cell lymphoma \u2013 a case report"],"prefix":"10.1038","volume":"5","author":[{"given":"Alicja M.","family":"Gruszka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Rabascio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Cannella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simona","family":"Sammassimo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanna","family":"Andreola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuliana","family":"Gregato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Faretta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelica","family":"Calleri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rita","family":"De Molfetta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giancarlo","family":"Pruneri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Bertolini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Myriam","family":"Alcalay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,10,6]]},"reference":[{"key":"BFsrep14829_CR1","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1002\/ajh.23691","volume":"89","author":"E Jabbour","year":"2014","unstructured":"Jabbour, E. & Kantarjian, H. Chronic myeloid leukemia: 2014 update on diagnosis, monitoring and management. Am J Hematol 89, 547\u2013556 (2014).","journal-title":"Am J Hematol"},{"key":"BFsrep14829_CR2","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.critrevonc.2014.11.001","volume":"93","author":"K Yang","year":"2014","unstructured":"Yang, K. & Fu, L. W. Mechanisms of resistance to BCR-ABL TKIs and the therapeutic strategies: A review. Crit Rev Oncol Hematol 93, 277\u201392 (2014).","journal-title":"Crit Rev Oncol Hematol"},{"key":"BFsrep14829_CR3","doi-asserted-by":"publisher","first-page":"4353","DOI":"10.1182\/blood-2011-06-362889","volume":"118","author":"D Verma","year":"2011","unstructured":"Verma, D. et al. Malignancies occurring during therapy with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and other hematologic malignancies. Blood 118, 4353\u20134358 (2011).","journal-title":"Blood"},{"key":"BFsrep14829_CR4","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.3109\/10428194.2012.666545","volume":"53","author":"BB Duman","year":"2012","unstructured":"Duman, B. B., Paydas, S., Disel, U., Besen, A. & Gurkan, E. Secondary malignancy after imatinib therapy: eight cases and review of the literature. Leuk Lymphoma 53, 1706\u20131708 (2012).","journal-title":"Leuk Lymphoma"},{"key":"BFsrep14829_CR5","doi-asserted-by":"publisher","first-page":"738428","DOI":"10.1155\/2014\/738428","volume":"2014","author":"J Maerki","year":"2014","unstructured":"Maerki, J., Katava, G., Siegel, D., Silberberg, J. & Bhattacharyya, P. K. Unusual case of simultaneous presentation of plasma cell myeloma, chronic myelogenous leukemia and a jak2 positive myeloproliferative disorder. Case Rep Hematol 2014, 738428, 10.1155\/2014\/738428 (2014).","journal-title":"Case Rep Hematol"},{"key":"BFsrep14829_CR6","first-page":"1141","volume":"54","author":"AM Gaman","year":"2013","unstructured":"Gaman, A. M., Dobrea, C. & Rotaru, I. A case of non-Hodgkin lymphoma in a patient with chronic myeloid leukemia. Rom J Morphol Embryol 54, 1141\u20131145 (2013).","journal-title":"Rom J Morphol Embryol"},{"key":"BFsrep14829_CR7","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1038\/sj.leu.2401606","volume":"14","author":"R Ichinohasama","year":"2000","unstructured":"Ichinohasama, R. et al. Ph-negative non-Hodgkin\u2019s lymphoma occurring in chronic phase of Ph-positive chronic myelogenous leukemia is defined as a genetically different neoplasm from extramedullary localized blast crisis: report of two cases and review of the literature. Leukemia 14, 169\u2013182 (2000).","journal-title":"Leukemia"},{"key":"BFsrep14829_CR8","doi-asserted-by":"publisher","first-page":"591","DOI":"10.3109\/02841869409121767","volume":"33","author":"P Boffetta","year":"1994","unstructured":"Boffetta, P. & Kaldor, J. M. Secondary malignancies following cancer chemotherapy. Acta Oncol 33, 591\u2013598 (1994).","journal-title":"Acta Oncol"},{"key":"BFsrep14829_CR9","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1517\/14740338.2015.1014340","volume":"14","author":"M Candelaria","year":"2015","unstructured":"Candelaria, M. & Duenas-Gonzalez, A. Therapy-related myelodysplastic syndrome. Expert Opin Drug Saf, 14, 655\u201365 (2015).","journal-title":"Expert Opin Drug Saf"},{"key":"BFsrep14829_CR10","first-page":"718","volume":"27","author":"Y Dincer","year":"2014","unstructured":"Dincer, Y. & Sezgin, Z. Medical Radiation Exposure and Human Carcinogenesis-Genetic and Epigenetic Mechanisms. Biomed Environ Sci 27, 718\u2013728 (2014).","journal-title":"Biomed Environ Sci"},{"key":"BFsrep14829_CR11","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/nrclinonc.2013.41","volume":"10","author":"LB Travis","year":"2013","unstructured":"Travis, L. B., Demark Wahnefried, W., Allan, J. M., Wood, M. E. & Ng, A. K. Aetiology, genetics and prevention of secondary neoplasms in adult cancer survivors. Nat Rev Clin Oncol 10, 289\u2013301 (2013).","journal-title":"Nat Rev Clin Oncol"},{"key":"BFsrep14829_CR12","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1038\/nrclinonc.2013.83","volume":"10","author":"GT Gibney","year":"2013","unstructured":"Gibney, G. T., Messina, J. L., Fedorenko, I. V., Sondak, V. K. & Smalley, K. S. Paradoxical oncogenesis\u2014the long-term effects of BRAF inhibition in melanoma. Nat Rev Clin Oncol 10, 390\u2013399 (2013).","journal-title":"Nat Rev Clin Oncol"},{"key":"BFsrep14829_CR13","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1158\/1055-9965.EPI-06-1069","volume":"16","author":"B Krishnan","year":"2007","unstructured":"Krishnan, B. & Morgan, G. J. Non-Hodgkin lymphoma secondary to cancer chemotherapy. Cancer Epidemiol Biomarkers Prev 16, 377\u2013380 (2007).","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"BFsrep14829_CR14","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1038\/leu.2009.46","volume":"23","author":"S Mustjoki","year":"2009","unstructured":"Mustjoki, S. et al. Clonal expansion of T\/NK-cells during tyrosine kinase inhibitor dasatinib therapy. Leukemia 23, 1398\u20131405 (2009).","journal-title":"Leukemia"},{"key":"BFsrep14829_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0165-4608(91)90228-M","volume":"55","author":"V Brito-Babapulle","year":"1991","unstructured":"Brito-Babapulle, V. & Catovsky, D. Inversions and tandem translocations involving chromosome 14q11 and 14q32 in T-prolymphocytic leukemia and T-cell leukemias in patients with ataxia telangiectasia. Cancer Genet Cytogenet 55, 1\u20139 (1991).","journal-title":"Cancer Genet Cytogenet"},{"key":"BFsrep14829_CR16","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/bcj.2014.78","volume":"4","author":"MA Laginestra","year":"2014","unstructured":"Laginestra, M. A. et al. Pathogenetic and diagnostic significance of microRNA deregulation in peripheral T-cell lymphoma not otherwise specified. Blood Cancer J 4, 259 (2014).","journal-title":"Blood Cancer J"},{"key":"BFsrep14829_CR17","doi-asserted-by":"publisher","first-page":"256","DOI":"10.4149\/neo_2011_03_256","volume":"58","author":"J Voglova","year":"2011","unstructured":"Voglova, J. et al. Incidence of second malignancies during treatment of chronic myeloid leukemia with tyrosine kinase inhibitors in the Czech Republic and Slovakia. Neoplasma 58, 256\u2013262 (2011).","journal-title":"Neoplasma"},{"key":"BFsrep14829_CR18","doi-asserted-by":"publisher","first-page":"e2015003","DOI":"10.4084\/MJHID.2015.003","volume":"7","author":"G Helbig","year":"2015","unstructured":"Helbig, G. et al. Occurrence of secondary malignancies in chronic myeloid leukemia during therapy with imatinib mesylate-single institution experience. Mediterr J Hematol Infect Dis 7, e2015003, 10.4084\/MJHID.2015.003 (2015).","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"BFsrep14829_CR19","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1111\/bjh.13346","volume":"169","author":"N Gunnarsson","year":"2015","unstructured":"Gunnarsson, N. et al. Second malignancies following treatment of chronic myeloid leukaemia in the tyrosine kinase inhibitor era. Br J Haematol 169, 683\u2013688 (2015).","journal-title":"Br J Haematol"},{"key":"BFsrep14829_CR20","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1038\/sj.leu.2401592","volume":"13","author":"JJ van Dongen","year":"1999","unstructured":"van Dongen, J. J. et al. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia. Leukemia 13, 1901\u20131928 (1999).","journal-title":"Leukemia"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep14829.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep14829","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep14829.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T16:03:28Z","timestamp":1672934608000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep14829"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10,6]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2015,12,7]]}},"alternative-id":["BFsrep14829"],"URL":"https:\/\/doi.org\/10.1038\/srep14829","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10,6]]},"assertion":[{"value":"10 April 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"14829"}}